Bristol Myers joins the legal fight over incoming Medicare drug price negotiations
Bristol Myers Squibb late last week joined Merck and the US Chamber of Commerce in challenging the Biden administration’s signature drug pricing reform — allowing, for the first time ever, Medicare to negotiate and rein in drug prices.
In its suit, filed in a New Jersey district court, BMS’ lawyers from Jones Day (the same firm hired by Merck) joined Merck in taking issue with the Inflation Reduction Act’s alleged violations of the First and Fifth Amendments, writing:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.